drugset / Trial / NCT02879305

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)

NCT02879305

Phase 3 Completed 2964 enrolled GlaxoSmithKline
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this multi-center event-driven study in participants with anemia associated with chronic kidney disease (CKD) to evaluate the safety and efficacy of daprodustat.

Timeline

Start
2016-09-28
Primary completion
2020-11-09
Completion
2020-11-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Daprodustat Small molecule Oral
Comparator Darbepoetin alfa Protein / enzyme biologic Subcutaneous
Comparator epoetin alfa Protein / enzyme biologic Intravenous